This page shows the latest Namenda news and features for those working in and with pharma, biotech and healthcare.
US for former blockbuster antidepressant Lexapro (escitalopram), as well as generic competition from 2015 for Alzheimer's disease therapy Namenda (memantine). ... With Lexapro and Namenda accounting for more than three quarters of company turnover at
Regardless, it has been 10 years since the last new Alzheimer's treatment reached the market - Lundbeck's glutamate (NMDA) antagonist Ebixa (memantine), which is sold as Namenda by Forest Labs
He said: "We have been working diligently for the past seven years to build a solid product development pipeline that will more than replace the loss of Lexapro and Namenda following
Lexapro (escitalopram) and its Alzheimer's drug Namenda (memantine) lose their patent protection in the coming years. . ... expiration for both Lexapro in 2012 and Namenda in 2015 and provide growth," he said.
Additionally, a patch formulation of donepezil is in development. Also approved for the treatment of moderate-to-severe AD is memantine (Namenda, Forest Laboratories), which was the first NMDA receptor antagonist
revenues lost due to patent expiration for Lexapro in 2012 and [the Alzheimer's drug] Namenda (memantine) in 2015.".
More from news
Approximately 0 fully matching, plus 13 partially matching documents found.
Not disclosed. Adamas. Forest. Completion of studies for the NDA of a fixed dosed combination of Namenda and donepezil, Forest has exclusive US commercialisation rights.
Development / commercialisation. Fixed dose combination of Namenda and donepezil for AD.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...